How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?

What happened: Eli Lilly ($LLY) is set to report third-quarter results on Oct. 29, 2026, with investors focused on its GLP-1 portfolio, including Mounjaro, Zepbound and newly approved oral therapy Foundayo. Key numbers: Mounjaro and Zepbound combined sales were $27.7 billion in the first half of 2026, up about 88% year over year and roughly 65% of total revenues. Why it matters: The GLP-1 franchise underpins Lilly's 2026 revenue outlook, and Q3 is the first full quarter with Medicare access for Foundayo through the GLP-1 Bridge program, a channel investors will watch. Market: -0.1% today ($1,255.49), +16.6% YTD, 0.1x vol — as of 14:18 UTC

Eli Lilly ($LLY) is set to report third-quarter results on Oct. 29, 2026, with investors focused on its GLP-1 portfolio, including Mounjaro, Zepbound and newly approved oral therapy Foundayo.

The GLP-1 franchise underpins Lilly's 2026 revenue outlook, and Q3 is the first full quarter with Medicare access for Foundayo through the GLP-1 Bridge program, a channel investors will watch. Market: -0.1% today ($1,255.49), +16.6% YTD, 0.1x vol — as of 14:18 UTC